Has Peter Chang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,049,938 in general payments to Peter Chang, MD across 1,181 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Chang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Chang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Chang, MD

Ophthalmology · Waltham, MANPI 1801107859

Payments from drug & device makers

$1,049,938in general payments, 2019–2025

Across 1,181 payments — averaging $889.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Mallinckrodt Hospital Products Inc.$610K
Eyepoint US, Inc.$159K
Bausch & Lomb Americas Inc.$66K
Alimera Sciences, Inc.$65K
Regeneron Healthcare Solutions, Inc.$53K
ANI Pharmaceuticals, Inc.$20K
plus $77K from 39 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Mallinckrodt Hospital Products Inc.	469	$609,690
Eyepoint US, Inc.	118	$158,735
Bausch & Lomb Americas Inc.	83	$66,262
Alimera Sciences, Inc.	78	$64,936
Regeneron Healthcare Solutions, Inc.	36	$52,717
ANI Pharmaceuticals, Inc.	35	$20,310
AbbVie(2 entities)	104	$16,688
Alcon	23	$14,683
Astellas Pharma US Inc	14	$13,481
Boehringer Ingelheim	5	$12,276
X4 Pharmaceuticals, Inc.	1	$6,000
Genentech USA, Inc.	18	$3,277
Dutch Ophthalmic, USA	10	$1,842
Genentech, Inc.	2	$1,680
Boehringer Ingelheim Pharma GmbH & Co.kg	1	$935
Sun Pharmaceutical Industries Inc.	24	$637
Dompe US, Inc.	17	$567
Bausch & Lomb, A Division Of Bausch Health US, LLC	18	$486
Samsara Vision	3	$415
Tarsus Pharmaceuticals, Inc.	8	$375
Oyster Point Pharma, Inc.	12	$360
Beaver-visitec International, Inc.	1	$350
Aerie Pharmaceuticals, Inc.	6	$330
Ocular Therapeutix, Inc.	18	$324
Sight Sciences, Inc.	3	$302
Mallinckrodt Enterprises LLC	9	$290
Kala Pharmaceuticals, Inc.	12	$268
Amgen(2 entities)	12	$243
Oculus Surgical Inc.	2	$206
Novartis	10	$199
Harrow Eye, LLC	2	$199
Biogen	1	$150
NEW World Medical,inc.	1	$112
Astellas Pharma Global Development	1	$109
Eyevance Pharmaceuticals LLC	7	$105
Johnson & Johnson Surgical Vision, Inc.	1	$87
Rayner Intraocular Lenses Limited	3	$66
Biotissue Holdings Inc.	4	$53
Apellis Pharmaceuticals, Inc.	2	$40
Coherus Oncology, Inc.	1	$38
Thea Pharma Inc.	2	$36
Neurotech Pharmaceuticals, Inc.	1	$24
Shire North American Group Inc	1	$24
Glaukos Corporation	1	$18
Ivantis, Inc	1	$13

How this compares

$1,049,938 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$2,800,020

Medicare patients

1,024

Services billed

36,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Waltham

Stephen AnesiWaltham$922K
Charles FosterWaltham$888K
Jonathan TalamoWaltham$225K
Nandini VenkateswaranWaltham$214K
Gail TorkildsenAndover$5.1M
David LallySpringfield$4.5M
Jennifer SunBoston$4.2M
Lloyd AielloBoston$3.1M
Rishi SinghBoston$2.5M
Rachel HuckfeldtStoneham$1.7M

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →